<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>IFEX- ifosfamide injection, powder, for solution </strong><br>Baxter Healthcare Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use IFEX safely and effectively.  See full prescribing information for IFEX.<br><br>IFEX (ifosfamide) for injection, intravenous use<br>Initial U.S. Approval: 1988</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span>, <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">NEUROTOXICITY</span>, and UROTOXICITY</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span>.</span></h1>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> can be severe and lead to fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#i4i_section_id_85148797-9d6e-483c-bb4e-77af400125a0">5.1</a>)</dd>
<dt>•</dt>
<dd>CNS toxicities can be severe and result in <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (<a href="#i4i_section_id_8ef13cdf-a78d-4dd1-bc6c-a5c28c3dc63c">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> can be severe and result in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.  <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">Hemorrhagic cystitis</span> can be severe.  (<a href="#i4i_section_id_ca7d533a-e48c-4411-a462-73a3e8f9bffd">5.3</a>)</dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span>, <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">NEUROTOXICITY</span>, and UROTOXICITY</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span>.</span></h1>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> can be severe and lead to fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#i4i_section_id_85148797-9d6e-483c-bb4e-77af400125a0">5.1</a>)</dd>
<dt>•</dt>
<dd>CNS toxicities can be severe and result in <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (<a href="#i4i_section_id_8ef13cdf-a78d-4dd1-bc6c-a5c28c3dc63c">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> can be severe and result in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.  <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">Hemorrhagic cystitis</span> can be severe.  (<a href="#i4i_section_id_ca7d533a-e48c-4411-a462-73a3e8f9bffd">5.3</a>)</dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">IFEX is an alkylating drug indicated for use in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer.  It should be used in combination with mesna for prophylaxis of <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>. <a href="#i4i_indications_id_0377dd33-1ab5-4b16-8a71-69829de71154">(1) </a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Dosage and duration of treatment and/or treatment intervals depend on the scheme of combination therapy, the patient’s general state of health and organ function, and the results of laboratory monitoring. (<a href="#i4i_dosage_admin_id_4b39ea41-f401-4b31-9187-64dc13103870">2</a>) </p>
<dl>
<dt>•</dt>
<dd>IFEX should be administered as a slow intravenous infusion lasting a minimum of 30 minutes at a dose of 1.2 grams per m<span class="Sup">2</span> per day for 5 consecutive days. (<a href="#i4i_dosage_admin_id_4b39ea41-f401-4b31-9187-64dc13103870">2</a>)</dd>
<dt>•</dt>
<dd>Treatment is repeated every 3 weeks or after recovery from hematologic toxicity. (<a href="#i4i_dosage_admin_id_4b39ea41-f401-4b31-9187-64dc13103870">2</a>)</dd>
<dt>•</dt>
<dd>To prevent bladder toxicity, IFEX should be given with extensive hydration consisting of at least 2 liters of oral or intravenous fluid per day. (<a href="#i4i_dosage_admin_id_4b39ea41-f401-4b31-9187-64dc13103870">2</a>, <a href="#i4i_section_id_ca7d533a-e48c-4411-a462-73a3e8f9bffd">5.3</a>)</dd>
<dt>•</dt>
<dd>Mesna should be used to reduce the incidence of <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>. (<a href="#i4i_dosage_admin_id_4b39ea41-f401-4b31-9187-64dc13103870">2</a>)</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Single dose vials: 1 gram, 3 grams (<a href="#i4i_dosage_form_strength_id_8a7a908c-6655-4b54-b665-0148fcc3f2f9">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to administration of ifosfamide. (<a href="#i4i_contraindications_id_7fc71884-fe4e-42e1-9afb-6e7207dc789b">4</a>)</dd>
<dt>•</dt>
<dd>Urinary outflow obstruction. (<a href="#i4i_contraindications_id_7fc71884-fe4e-42e1-9afb-6e7207dc789b">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>: Can be severe and lead to fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  Monitor blood counts prior to and at intervals after treatment. (<a href="#i4i_section_id_85148797-9d6e-483c-bb4e-77af400125a0">5.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span>: Severe and fatal <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> can occur. Carefully monitor the patient for CNS toxicity and other neurotoxic effects.  Discontinue therapy should <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> develop. (<a href="#i4i_section_id_8ef13cdf-a78d-4dd1-bc6c-a5c28c3dc63c">5.2</a>) </dd>
<dt>•</dt>
<dd>Urotoxicity: Severe <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> can occur. Monitor for <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> with serum and urine chemistries.  Mesna should be used to reduce <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>. (<a href="#i4i_section_id_ca7d533a-e48c-4411-a462-73a3e8f9bffd">5.3</a>) </dd>
<dt>•</dt>
<dd>Cardiotoxicity: <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, other ECG changes, and <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> can occur and result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Use with caution in patients with cardiac risk factors and in patients with preexisting cardiac disease.  The risk of cardiotoxicity is dose dependent. (<a href="#i4i_section_id_84a27121-aca4-408a-8bb4-3b1f65999a35">5.4</a>) </dd>
<dt>•</dt>
<dd>Pulmonary toxicity: <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, and other forms of pulmonary toxicity with fatal outcomes can occur. Monitor for signs and symptoms of pulmonary toxicity and treat as clinically indicated (<a href="#i4i_section_id_b364087b-ab49-42b8-ab25-61fb150022a9">5.5</a>) </dd>
<dt>•</dt>
<dd>Secondary malignancies as late sequelae have occurred. (<a href="#i4i_section_id_10ed0019-a7af-40dc-9f24-78c24ed9fc75">5.6</a>) </dd>
<dt>•</dt>
<dd>Pregnancy:  Can cause fetal harm.  Women should not become pregnant and men should not father a child during therapy. (<a href="#i4i_section_id_c7d42fd1-36e1-4d63-9d9a-f5ee2d60bac2">5.8</a>) </dd>
<dt>•</dt>
<dd>Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported. (<a href="#i4i_section_id_1dece040-c07b-4168-84f1-fe7a05efea84">5.10</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">In clinical trials of ifosfamide monotherapy, the most common (≥ 10%) adverse reactions were <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, CNS toxicity, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#i4i_section_id_160695d2-fd34-4093-9e72-37fa20d442eb">6.1</a>) </p>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at phone: 1 866 888 2472 or FDA at 1-800-FDA-1088 or <span class="Bold"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span>. </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>CYP3A4 Inducers:  monitor for increased toxicity when used in combination with CYP3A4 inducers. (<a href="#i4i_section_id_908657e5-a7a6-48f4-92ce-4c7f0e9ea06f">7.1</a>)</dd>
<dt>•</dt>
<dd>CYP3A4 Inhibitors: use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (<a href="#i4i_section_id_49b9acfb-bd5a-47d4-bfbd-46cfbffd2de0">7.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy: <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span> and neonatal <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. (<a href="#i4i_pregnancy_id_dc1829a4-53a1-44c3-8c8a-46940d7b1861">8.1</a>)</dd>
<dt>•</dt>
<dd>Geriatric use: dose selection should be cautious. (<a href="#i4i_geriatric_use_id_8310e877-4422-4d7a-a739-644ac1efd8ba">8.5</a>)</dd>
<dt>•</dt>
<dd>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: monitor for toxicity and consider dose reduction as needed ( <a href="#i4i_section_id_aa34a324-1d25-4cc2-96ee-b37d4b268b6a">8.6</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span>,  <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">NEUROTOXICITY</span>,  and UROTOXICITY</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Central Nervous System Toxicity, <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Renal and Urothelial Toxicity and Effects</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Cardiotoxicity</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Pulmonary Toxicity</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Secondary Malignancies</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Veno-occlusive Liver Disease</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Pregnancy</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Effects on Fertility</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> and Cross-sensitivity</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Impairment of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Nursing</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Adverse Reactions from Clinical Trials</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Inducers of CYP3A4</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Inhibitors of CYP3A4</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="i4i_boxed_warning_id_b3f28bda-a21d-46c3-95d7-d85d0771cd57"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span>,  <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">NEUROTOXICITY</span>,  and UROTOXICITY</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> can be severe and lead to fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  Monitor blood counts prior to and at intervals after each treatment cycle.  CNS toxicities can be severe and result in <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Monitor for CNS toxicity and discontinue treatment for <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>.  <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> can be severe and result in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.  <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">Hemorrhagic cystitis</span> can be severe and can be reduced by the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of mesna. <a href="#i4i_warnings_precautions_id_2bf4b8fd-98db-4cd6-a836-bf59e7d8b5e9">[see Warnings and Precautions (5.1-5.3)]</a></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_0377dd33-1ab5-4b16-8a71-69829de71154"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">IFEX is indicated for use in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer.  It should be used in combination with mesna for prophylaxis of <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_4b39ea41-f401-4b31-9187-64dc13103870"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">IFEX should be administered intravenously at a dose of 1.2 grams per m<span class="Sup">2</span> per day for 5 consecutive days.  Treatment is repeated every 3 weeks or after recovery from hematologic toxicity.</p>
<p>In order to prevent bladder toxicity, IFEX should be given with extensive hydration consisting of at least 2 liters of oral or intravenous fluid per day. Mesna should be used to reduce the incidence of <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>. IFEX should be administered as a slow intravenous infusion lasting a minimum of 30 minutes. Studies of IFEX in patients with hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> have not been conducted [see Use in Specific Populations (<a href="#i4i_section_id_aa34a324-1d25-4cc2-96ee-b37d4b268b6a">8.6</a>, <a href="#i4i_section_id_f7ff40b0-3e36-446a-82cb-08375353364e">8.7</a>)]<span class="Italics">.</span></p>
<p>Injections are prepared for parenteral use by adding <span class="Italics">Sterile Water for Injection, USP</span> or <span class="Italics">Bacteriostatic Water for Injection, USP</span> (benzyl alcohol or parabens preserved), to the vial and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> to dissolve.  Before parenteral administration, the substance must be completely dissolved.  Use the quantity of diluents shown below to constitute the product:</p>
<table width="100%">
<col width="26%">
<col width="26%">
<col width="26%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First">Dosage Strength</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">Quantity of Diluent</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Final Concentration</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">1 gram</p></td>
<td class="Botrule Lrule" align="center"><p class="First">20 mL</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg per mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">3 grams</p></td>
<td class="Botrule Lrule" align="center"><p class="First">60 mL</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 mg per mL</p></td>
</tr>
</tbody>
</table>
<p>Solutions of ifosfamide may be diluted further to achieve concentrations of 0.6 to 20 mg/mL in the following fluids:</p>
<p> 5% Dextrose Injection, USP</p>
<p> 0.9% Sodium Chloride Injection, USP</p>
<p> Lactated Ringer’s Injections, USP</p>
<p> Sterile Water for Injection, USP</p>
<p>Because essentially identical stability results were obtained for Sterile Water admixtures as for the other admixtures (5% Dextrose Injection, 0.9% Sodium Chloride Injection, and Lactated Ringer’s Injection), the use of large volume parenteral glass bottles, VIAFLEX bags or PAB bags that contain intermediate concentrations or mixtures of excipients (e.g., 2.5% Dextrose Injection, 0.45% Sodium Chloride Injection, or 5% Dextrose and 0.9% Sodium Chloride Injection) is also acceptable.</p>
<p>Constituted or constituted and further diluted solutions of IFEX should be refrigerated and used within 24 hours.  Benzyl-alcohol-containing solutions can reduce the stability of ifosfamide.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_8a7a908c-6655-4b54-b665-0148fcc3f2f9"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">1 gram single-dose vial</p>
<p>3 gram single-dose vial</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_7fc71884-fe4e-42e1-9afb-6e7207dc789b"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">IFEX is contraindicated in patients with:</p>
<dl>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to administration of ifosfamide.</dd>
<dt>•</dt>
<dd>Urinary outflow obstruction.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_2bf4b8fd-98db-4cd6-a836-bf59e7d8b5e9"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_85148797-9d6e-483c-bb4e-77af400125a0"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Treatment with ifosfamide may cause <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> and significant suppression of immune responses, which can lead to severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  Fatal outcomes of ifosfamide-associated <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> have been reported.  Ifosfamide-induced <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> can cause <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (associated with a higher risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.  The nadir of the leukocyte count tends to be reached approximately during the second week after administration.  When IFEX is given in combination with other chemotherapeutic/hematotoxic agents and/or radiation therapy, severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is frequently observed.  The risk of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is dose-dependent and is increased with administration of a single high dose compared with fractionated administration.  The risk of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is also increased in patients with reduced renal function.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> has led to serious, sometimes fatal, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> and <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span> also have been reported.  <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> reported with ifosfamide include <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonias</span>, as well as other bacterial, fungal, viral, and parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  Latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be reactivated.  In patients treated with ifosfamide, reactivation has been reported for various <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>.  <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> must be treated appropriately.  Antimicrobial prophylaxis may be indicated in certain cases of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> at the discretion of the managing physician.  In case of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span>, antibiotics and/or antimycotics must be given.  Close hematologic monitoring is recommended.  White blood cell (WBC) count, platelet count and hemoglobin should be obtained prior to each administration and at appropriate intervals after administration.  Unless clinically essential, IFEX should not be given to patients with a WBC count below 2000/µL and/or a platelet count below 50,000/µL.</p>
<p>IFEX should be given cautiously, if at all, to patients with presence of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, severe <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> or compromised bone marrow reserve, as indicated by <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, extensive bone marrow <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>, prior radiation therapy, or prior therapy with other cytotoxic agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ef13cdf-a78d-4dd1-bc6c-a5c28c3dc63c"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Central Nervous System Toxicity, <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span></h2>
<p class="First">Administration of ifosfamide can cause CNS toxicity and other neurotoxic effects.  The risk of CNS toxicity and other neurotoxic effects necessitates careful monitoring of the patient.  Neurologic manifestations consisting of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> behavior, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and in some instances, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, have been reported following IFEX therapy.  There have also been reports of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> associated with ifosfamide use.</p>
<p>Ifosfamide <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> may become manifest within a few hours to a few days after first administration and in most cases resolves within 48 to 72 hours of ifosfamide discontinuation.  Symptoms may persist for longer periods of time.  Supportive therapy should be maintained until their complete resolution.  Occasionally, recovery has been incomplete.  Fatal outcomes of CNS toxicity have been reported.  Recurrence of CNS toxicity after several uneventful treatment courses has been reported.  If <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> develops, administration of ifosfamide should be discontinued.  </p>
<p>Due to the potential for additive effects, drugs acting on the CNS (such as antiemetics, sedatives, narcotics, or antihistamines) must be used with particular caution or, if necessary, be discontinued in case of ifosfamide-induced <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>.  </p>
<p>Manifestations of CNS toxicity may impair a patient’s ability to operate an automobile or other heavy machinery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ca7d533a-e48c-4411-a462-73a3e8f9bffd"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Renal and Urothelial Toxicity and Effects</h2>
<p class="First">Ifosfamide is both nephrotoxic and urotoxic.  Glomerular and tubular kidney function must be evaluated before commencement of therapy as well as during and after treatment.  Monitor urinary sediment regularly for the presence of erythrocytes and other signs of uro/<span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>.</p>
<p>Monitor serum and urine chemistries, including phosphorus and potassium regularly.  Administer appropriate replacement therapy as indicated.  Renal parenchymal and <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">tubular necrosis</span> have been reported in patients treated with ifosfamide.  <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Acute tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, and <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span> secondary to ifosfamide therapy have been reported, and fatal outcome from <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> has been documented.</p>
<p>Disorders of renal function, (glomerular and tubular) following ifosfamide administration are very common.  Manifestations include a decrease in glomerular filtration rate, increased serum creatinine, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, enzymuria, <span class="product-label-link" type="condition" conceptid="442282" conceptname="Urinary casts">cylindruria</span>, <span class="product-label-link" type="condition" conceptid="4262444" conceptname="Aminoaciduria">aminoaciduria</span>, phosphaturia, and <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> as well as tubular <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>.  <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span>, <span class="product-label-link" type="condition" conceptid="197921" conceptname="Renal osteodystrophy">renal rickets</span>, and <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> in children as well as <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> in adults also have been reported.  Development of a syndrome resembling <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span> (syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span>) has been reported with ifosfamide.  </p>
<p>Tubular damage may become apparent during therapy, months or even years after cessation of treatment.  Glomerular or tubular dysfunction may resolve with time, remain stable, or progress over a period of months or years, even after completion of ifosfamide treatment.  </p>
<p>The risk and expected benefits of ifosfamide therapy should be carefully weighed when considering the use of ifosfamide in patients with preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or reduced nephron reserve.</p>
<p>Urotoxic side effects, especially <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>, have been very commonly associated with the use of IFEX.  These urotoxic effects can be reduced by <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of mesna.</p>
<p><span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">Hemorrhagic cystitis</span> requiring blood transfusion has been reported with ifosfamide.  The risk of <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span> is dose-dependent and increased with administration of single high doses compared to fractionated administration.  <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">Hemorrhagic cystitis</span> after a single dose of ifosfamide has been reported.  Past or concomitant radiation of the bladder or busulfan treatment may increase the risk for <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>.  </p>
<p>Before starting treatment, it is necessary to exclude or correct any <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">urinary tract obstructions</span> [see <a href="#i4i_contraindications_id_7fc71884-fe4e-42e1-9afb-6e7207dc789b">Contraindications (4)</a>]. </p>
<p>During or immediately after administration, adequate amounts of fluid should be ingested or infused to force dieresis in order to reduce the risk of urinary tract toxicity.  Obtain a urinalysis prior to each dose of IFEX.  If <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">microscopic hematuria</span> (greater than 10 RBCs per high power field) is present, then subsequent administration should be withheld until complete resolution.  Further administration of IFEX should be given with vigorous oral or parenteral hydration.</p>
<p>Ifosfamide should be used with caution, if at all, in patients with active <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_84a27121-aca4-408a-8bb4-3b1f65999a35"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Cardiotoxicity</h2>
<p class="First">Manifestations of cardiotoxicity reported with ifosfamide treatment include:</p>
<dl>
<dt>•</dt>
<dd>Supraventricular or <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, including atrial/<span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, pulseless <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span></dd>
<dt>•</dt>
<dd>Decreased QRS voltage and ST-segment or T-wave changes</dd>
<dt>•</dt>
<dd>Toxic <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> leading to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with congestion and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">Pericardial effusion</span>, fibrinous <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, and epicardial <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span></dd>
</dl>
<p>Fatal outcome of ifosfamide-associated cardiotoxicity has been reported.  </p>
<p>The risk of developing cardiotoxic effects is dose-dependent.  It is increased in patients with prior or concomitant treatment with other cardiotoxic agents or radiation of the cardiac region and, possibly, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Particular caution should be exercised when ifosfamide is used in patients with risk factors for cardiotoxicity and in patients with preexisting cardiac disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b364087b-ab49-42b8-ab25-61fb150022a9"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Pulmonary Toxicity</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, and other forms of pulmonary toxicity have been reported with ifosfamide treatment.  Pulmonary toxicity leading to <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> as well as fatal outcome has also been reported. Monitor for signs and symptoms of pulmonary toxicity and treat as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_10ed0019-a7af-40dc-9f24-78c24ed9fc75"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Secondary Malignancies</h2>
<p class="First">Treatment with ifosfamide involves the risk of secondary tumors and their precursors as late sequelae.  The risk of myelodysplastic alterations, some progressing to <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">acute leukemias</span>, is increased.  Other malignancies reported after use of ifosfamide or regimens with ifosfamide include <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, thyroid cancer, and <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span>.</p>
<p>The secondary malignancy may develop several years after chemotherapy has been discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7839fd6b-65ed-41ee-bf0f-e15054a40296"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Veno-occlusive Liver Disease</h2>
<p class="First">Veno-occlusive liver disease has been reported with chemotherapy that included ifosfamide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7d42fd1-36e1-4d63-9d9a-f5ee2d60bac2"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Pregnancy</h2>
<p class="First">IFEX can cause fetal harm when administered to a pregnant woman. <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">Fetal growth retardation</span> and neonatal <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> have been reported following exposure to ifosfamide-containing chemotherapy regimens during pregnancy. Ifosfamide is genotoxic and mutagenic in male and female germ cells.  Embryotoxic and teratogenic effects have been observed in mice, rats and rabbits at doses 0.05 to 0.075 times the human dose.</p>
<p>Women should not become pregnant and men should not father a child during therapy with ifosfamide.  Further, men should not father a child for up to 6 months after the end of therapy.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug or after treatment, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58d41e3a-7876-4529-ab68-6f6f60ab2f2a"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Effects on Fertility</h2>
<p class="First">Ifosfamide interferes with oogenesis and spermatogenesis.  <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span>, and <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> in both sexes have been reported.  Development of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> appears to depend on the dose of ifosfamide, duration of therapy, and state of gonadal function at the time of treatment.  <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> may be irreversible in some patients.</p>
<p>Female Patients</p>
<p><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> has been reported in patients treated with ifosfamide.  The risk of permanent chemotherapy-induced <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> increases with age.  Pediatric patients treated with ifosfamide during prepubescence subsequently may not conceive and those who retain ovarian function after completing treatment are at increased risk of developing <span class="product-label-link" type="condition" conceptid="198715" conceptname="Premature menopause">premature menopause</span>.</p>
<p>Male Patients</p>
<p>Men treated with ifosfamide may develop <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span> or <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span>.  Pediatric patients treated with ifosfamide during prepubescence might not develop secondary sexual characteristics normally, but may have <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span> or <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span>.  <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">Azoospermia</span> may be reversible in some patients, though the reversibility may not occur for several years after cessation of therapy.  Sexual function and libido are generally unimpaired in these patients.  Some degree of <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> may occur.  Patients treated with ifosfamide have subsequently fathered children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1dece040-c07b-4168-84f1-fe7a05efea84"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> and Cross-sensitivity</h2>
<p class="First">Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported in association with ifosfamide.</p>
<p>Cross-sensitivity between oxazaphosphorine cytotoxic agents has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c112bf08-7bdf-4806-9d9e-e9690416d3c0"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Impairment of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing</h2>
<p class="First">Ifosfamide may interfere with normal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e50274fc-5e19-46b8-a01b-1d164519e730"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Nursing</h2>
<p class="First">Ifosfamide is excreted in breast milk.  Women must not breastfeed during treatment with ifosfamide [see Use in Specific Populations (8.3)].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_b2addcd3-9cce-4d96-b600-3c1297ee0ba8"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_160695d2-fd34-4093-9e72-37fa20d442eb"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Adverse Reactions from Clinical Trials</h2>
<p class="First">Because clinical trials are conducted from widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.  The adverse reactions and frequencies below are based on 30 publications describing clinical experience with fractionated administration of ifosfamide as monotherapy with a total dose of 4 to 12 g/m<span class="Sup">2</span> per course.</p>
<table width="100%">
<col width="38%">
<col width="37%">
<col width="25%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>The following adverse reaction terms have been reported for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.  For <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span>, see below.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>The frequency category of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> is based on the frequency of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> &lt;3 x 10<span class="Sup">3</span>/µL [42.5% (150/353) not shown in table] and &lt;1 x 10<span class="Sup">3</span>/µL; a relevant percentage ratio cannot be calculated for the pooled data and thus the conservative frequency category of “Very common? was included in the table.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> may also be complicated by <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> with fatal outcome has been reported.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Frequency of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> is based on the frequency of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> &lt;100 x 10<span class="Sup">3</span>/µL [12.2% (24/196) not shown in table] and &lt;50 x 10<span class="Sup">3</span>/µL; a relevant percentage ratio cannot be calculated from the pooled data and thus the conservative frequency of “Very common? was included in the table.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Includes cases reported as <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and decrease in hemoglobin/hematocrit.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> with <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has been reported.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">Þ</a></dt>
<dd>Central nervous system toxicity was reported to be manifested by the following signs and symptoms: Abnormal behavior, <span class="product-label-link" type="condition" conceptid="4197184" conceptname="Pseudobulbar affect">Affect lability</span> <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggression</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">Aphasia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span>, <span class="product-label-link" type="condition" conceptid="4046815" conceptname="Dysdiadochokinesis">Cerebellar syndrome</span>, Cerebral function deficiency, <span class="product-label-link" type="condition" conceptid="40480615" conceptname="Cognitive disorder">Cognitive disorder</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, Cranial nerve dysfunction, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressed state</span> of consciousness, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">Disorientation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="4168553" conceptname="Electroencephalogram abnormal">Electroencephalogram abnormal</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="4245464" conceptname="Flat affect">Flat affect</span>. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, Ideation, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">Memory impairment</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood change</span>, <span class="product-label-link" type="condition" conceptid="4203631" conceptname="Motor dysfunction">Motor dysfunction</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">Myoclonus</span>, Progressive loss of brainstem reflexes, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reaction</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span>.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">ß</a></dt>
<dd>Cardiotoxicity was reported as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>.  Fatal outcome has been reported.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">à</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> leading to <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and fatal outcome has been reported.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">è</a></dt>
<dd>Hepatotoxicity was reported as increases in liver enzymes, i.e., serum <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>, serum <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span>, alkaline phosphatase, gamma-glutamyltransferase and lactate dehydrogenase, increased bilirubin, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="196455" conceptname="Hepatorenal syndrome">hepatorenal syndrome</span>.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">ð</a></dt>
<dd>Frequency of <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span> is estimated based on the frequency of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>.  Reported symptoms of <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span> included <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span> and <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span>.  See also Post-marketing Adverse Reactions (6.2).</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">ø</a></dt>
<dd>Renal dysfunction was reported to be manifested as: <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>; fatal outcomes have been reported), Serum creatinine increased, BUN increased, Creatinine clearance decreased, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">Glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">Uremia</span>, Creatinine clearance increased.  Renal structural damage was reported to be manifested as: <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Acute tubular necrosis</span>, renal parenchymal damage, Enzymuria, <span class="product-label-link" type="condition" conceptid="442282" conceptname="Urinary casts">Cylindruria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span>.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">ý</a></dt>
<dd>Includes cases reported as <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> and irritation of the venous walls.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">£</a></dt>
<dd>Frequency of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">neutropenic fever</span>: Includes cases reported as granulocytopenic <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">System Organ Class (SOC)</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Percentage (Ratio)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">INFESTATIONS</span></p></td>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">9.9%</p>
<p>(112/1128)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="5"><p class="First">BLOOD AND LYMPHATIC SYSTEM DISORDERS</p></td>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> (any)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">--<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule">
<p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></p>
<p>&lt;1 x 10<span class="Sup">3</span>/µL</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">43.5%</p>
<p>(267/614)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a> (any)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">--<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule">
<p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, </p>
<p>50 x 10<span class="Sup">3</span>/µL</p>
</td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">4.8%</p>
<p>(35/729)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">37.9%</p>
<p>(202/533)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">METABOLISM AND NUTRITION DISORDERS</p></td>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">1.1%</p>
<p>(15/1317)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">NERVOUS SYSTEM DISORDERS</span></p></td>
<td class="Botrule Lrule"><p class="First">Central nervous system toxicity<a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a><span class="Sup">,</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">Þ</a></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">15.4%</p>
<p>(154/1001)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.4%</p>
<p>(5/1317)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">CARDIAC DISORDERS</span></p></td>
<td class="Botrule Lrule"><p class="First">Cardiotoxicity<a name="footnote-reference-8" href="#footnote-8" class="Sup">ß</a></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.5%</p>
<p>(7/1317)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">VASCULAR DISORDERS</span></p></td>
<td class="Botrule Lrule"><p class="First">Hypotention<a name="footnote-reference-9" href="#footnote-9" class="Sup">à</a></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.3%</p>
<p>(4/1317)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">GASTROINTESTINAL DISORDERS</span></p></td>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">46.8%</p>
<p>(443/964)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.7%</p>
<p>(9/1317)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.3%</p>
<p>(4/1317)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">HEPATOBILIARY DISORDERS</p></td>
<td class="Botrule Lrule"><p class="First">Hepatotoxicity<a name="footnote-reference-10" href="#footnote-10" class="Sup">è</a></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">1.8%</p>
<p>(22/1190)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3"><p class="First">SKIN AND SUBCUTANEOUS TISSUES DISORDERS</p></td>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">89.6%</p>
<p>(540/603)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.08%</p>
<p>(1/1317)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">Papular rash</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.08%</p>
<p>(1/1317)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="1"><p class="First">RENAL AND URINARY DISORDERS</p></td>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">Hemorrhagic cystitis</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">--<a name="footnote-reference-11" href="#footnote-11" class="Sup">ð</a></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">   - without mesna</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">44.1%</p>
<p>(282/640)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">   - with mesna</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">21.3%</p>
<p>(33/155)</p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First">Macrohematuria</p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">   -  without mesna</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">11.1%</p>
<p>(66/594)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">    -  with mesna</p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">5.2%</p>
<p>(5/97)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Renal dysfunction<a name="footnote-reference-12" href="#footnote-12" class="Sup">ø</a></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Renal structural damage</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="4"><p class="First">GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONS</p></td>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">ý</a></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">2.8%</p>
<p>(37/1317)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Neutropenic fever</span><a name="footnote-reference-14" href="#footnote-14" class="Sup">£</a></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">1.0%</p>
<p>(13/1317)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule" align="center">
<p class="First">0.3%</p>
<p>(4/1317)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Unable to calculate</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0e77e3a2-a885-4229-9003-89c751626770"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been reported in the post-marketing experience, listed by MedDRA System Organ Class (SOC), then by Preferred Term in order of severity, where feasible. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">INFESTATIONS</span>:</p>
<p>The following manifestations have been associated with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> and <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> caused by ifosfamide: increased risk for and severity of infections†, pneumonias†, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> and <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span> (including fatal outcomes), as well as reactivation of latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including viral hepatitis†, <span class="Italics">Pneumocystis jiroveci</span>†, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="Italics">Strongyloides</span>, progressive multifocal leukoencephalopathy†, and other viral and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>.</p>
<p>† Severe <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> has led to serious, sometimes fatal, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>NEOPLASMS, BENIGN AND MALIGNANT AND UNSPECIFIED (INCL <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">CYSTS</span> AND <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">POLYPS</span>):</p>
<p>As treatment-related secondary malignancy*, <span class="product-label-link" type="condition" conceptid="138708" conceptname="Acute leukemia">Acute leukemia</span>* (<span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">Acute myeloid leukemia</span>)*, <span class="product-label-link" type="condition" conceptid="4103718" conceptname="Acute promyelocytic leukemia">Acute promyelocytic leukemia</span>*, <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">Acute lymphocytic leukemia</span>*, <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">Myelodysplastic syndrome</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> (Non-Hodgkin’s <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>), <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">Sarcomas</span>*, Renal cell carcinoma, Thyroid cancer</p>
<p>BLOOD AND LYMPHATIC SYSTEM DISORDERS:</p>
<p>Hematotoxicity*, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> manifested as <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Bone marrow failure</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>; Febrile bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>; <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">Disseminated intravascular coagulation</span>, <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic uremic syndrome</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, Neonatal <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">IMMUNE SYSTEM DISORDERS</span>:</p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>*, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reaction</span></p>
<p><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">ENDOCRINE DISORDERS</span>:</p>
<p>Syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>)</p>
<p>METABOLISM AND NUTRITION DISORDERS:</p>
<p><span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor lysis syndrome</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">Polydipsia</span></p>
<p>PSYCHIATRIC DISORDERS:</p>
<p><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">Panic attack</span>, <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">Catatonia</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">Paranoia</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">Delusion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">Delirium</span>, <span class="product-label-link" type="condition" conceptid="4111210" conceptname="Bradyphrenia">Bradyphrenia</span>, <span class="product-label-link" type="condition" conceptid="4339188" conceptname="Mutism">Mutism</span>, Mental status change, <span class="product-label-link" type="condition" conceptid="4273392" conceptname="Echolalia">Echolalia</span>, <span class="product-label-link" type="condition" conceptid="4294887" conceptname="Cluttering">Logorrhea</span>, <span class="product-label-link" type="condition" conceptid="4195445" conceptname="Perseveration">Perseveration</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">NERVOUS SYSTEM DISORDERS</span>:</p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span>*, <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">Status epilepticus</span> (convulsive and nonconvulsive), <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">reversible posterior leukoencephalopathy syndrome</span>, <span class="product-label-link" type="condition" conceptid="4027461" conceptname="Leukoencephalopathy">Leukoencephalopathy</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">Asterixis</span>, <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">Movement disorder</span>, <span class="product-label-link" type="condition" conceptid="4174262" conceptname="Polyneuropathy">Polyneuropathy</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">Dysesthesia</span>, Hypothesia, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">Neuralgia</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">Fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">Dysarthria</span></p>
<p><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">EYE DISORDERS</span>: </p>
<p><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Visual impairment</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye irritation</span></p>
<p>EAR AND LABYRINTH DISORDERS:</p>
<p><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Deafness</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hypoacusis</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></p>
<p><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">CARDIAC DISORDERS</span>: </p>
<p>Cardiotoxicity*, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>*, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular fibrillation</span>*, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">Ventricular tachycardia</span>*, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">Cardiogenic shock</span>*, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>*, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span>*, <span class="product-label-link" type="condition" conceptid="313209" conceptname="Left bundle branch hemiblock">Bundle branch block left</span>, <span class="product-label-link" type="condition" conceptid="314059" conceptname="Right bundle branch block">Bundle branch block right</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">Pericardial effusion</span>, Myocardial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">Left ventricular failure</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>*, <span class="product-label-link" type="condition" conceptid="4163710" conceptname="Dilated cardiomyopathy">Congestive cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">Myocarditis</span>*, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>*, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">Pericarditis</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">Atrial flutter</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="441872" conceptname="Supraventricular premature beats">Supraventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="441872" conceptname="Supraventricular premature beats">Premature atrial contractions</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">Ventricular extrasystoles</span>, Myocardial <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">Ejection fraction</span> decreased*, Electrocardiogram ST-segment abnormal, Electrocardiogram T-wave inversion, Electrocardiogram <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span> abnormal</p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">VASCULAR DISORDERS</span>:</p>
<p><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4227747" conceptname="Capillary leak syndrome">Capillary leak syndrome</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">Blood pressure decreased</span></p>
<p>RESPIRATORY, THORACIC, AND <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">MEDIASTINAL DISORDERS</span>:</p>
<p><span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">Respiratory failure</span>*, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Acute respiratory distress syndrome</span>*, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary hypertension</span>*, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span>* as manifested by <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">Pulmonary fibrosis</span>*, <span class="product-label-link" type="condition" conceptid="433233" conceptname="Mushroom workers' lung">Alveolitis allergic</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span>*, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span>*, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">GASTROINTESTINAL DISORDERS</span>:</p>
<p><span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">Cecitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">Enterocolitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="442121" conceptname="Mucosal ulcer">Mucosal ulceration</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary hypersecretion</span></p>
<p>HEPATOBILIARY DISORDERS:</p>
<p><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span>*, <span class="product-label-link" type="condition" conceptid="4143845" conceptname="Fulminant hepatitis">Hepatitis fulminant</span>*, Veno-occlusive liver disease, <span class="product-label-link" type="condition" conceptid="199837" conceptname="Portal vein thrombosis">Portal vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Cytolytic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">Cholestasis</span></p>
<p>SKIN AND SUBCUTANEOUS TISSUE DISORDERS:</p>
<p><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, Palmar-plantar erythrodysesthesia syndrome, Radiation recall <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">Skin necrosis</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">Facial swelling</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span>, <span class="product-label-link" type="condition" conceptid="4154924" conceptname="Macular eruption">Macular rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>, <span class="product-label-link" type="condition" conceptid="4172432" conceptname="Hyperpigmentation of skin">Skin hyperpigmentation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorder</span></p>
<p>MUSCULOSKELETAL AND <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">CONNECTIVE TISSUE DISORDER</span>:</p>
<p><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">Osteomalacia</span>, <span class="product-label-link" type="condition" conceptid="4189941" conceptname="Rickets">Rickets</span>, <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">Growth retardation</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">Muscle twitching</span></p>
<p>RENAL AND URINARY DISORDERS:</p>
<p><span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span>, <span class="product-label-link" type="condition" conceptid="4177206" conceptname="Tubulointerstitial nephritis">Tubulointerstitial nephritis</span>, <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">Nephrogenic diabetes insipidus</span>, Phosphaturia, <span class="product-label-link" type="condition" conceptid="4262444" conceptname="Aminoaciduria">Aminoaciduria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Polyuria</span>, <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">Enuresis</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Feeling of residual urine</span></p>
<p>Fatal outcomes from acute and <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span> have been documented.</p>
<p>REPRODUCTIVE SYSTEM AND <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">BREAST DISORDERS</span>:</p>
<p><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span>, <span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">Ovarian failure</span>, <span class="product-label-link" type="condition" conceptid="198715" conceptname="Premature menopause">Premature menopause</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4207977" conceptname="Disorder of ovary">Ovarian disorder</span>, Ovulation disorder, <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">Azoospermia</span>, <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">Oligospermia</span>, Impairment of spermatogenesis, Blood estrogen decreased, Blood gonadotrophin increased</p>
<p>CONGENITAL, FAMILIAL AND GENETIC DISORDERS:</p>
<p><span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">Fetal growth retardation</span></p>
<p>GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONS:</p>
<p>Multi-organ failure*, General physical deterioration, Injection/Infusion site reactions including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucosal inflammation</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p>
<p>* Including fatal outcomes</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_31def1e3-13e8-4cdd-bb22-dfbd60161b53"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Ifosfamide is a substrate for both CYP3A4 and CYP2B6.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_908657e5-a7a6-48f4-92ce-4c7f0e9ea06f"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Inducers of CYP3A4</h2>
<p class="First">CYP3A4 inducers (e.g., carbamazepine, phenytoin, fosphenytoin, phenobarbital, rifampin, St. John Wort) may increase the metabolism of ifosfamide to its active alkylating metabolites. CYP3A4 inducers may increase the formation of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Closely monitor patients taking ifosfamide with CYP3A4 inducers for toxicities and consider dose adjustment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49b9acfb-bd5a-47d4-bfbd-46cfbffd2de0"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Inhibitors of CYP3A4</h2>
<p class="First">CYP3A4 inhibitors (e.g., ketoconazole, fluconazole, itraconazole, sorafenib, aprepitant, fosaprepitant, grapefruit, grapefruit juice) may decrease the metabolism of ifosfamide to its active alkylating metabolites, perhaps decreasing the effectiveness of ifosfamide treatment. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_a28d42b2-ea03-498e-8be9-d4917330fd11"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_dc1829a4-53a1-44c3-8c8a-46940d7b1861"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_D_id_b96a4790-cc89-4442-8254-d09110b9b45e"></a><a name="section-8.1.1"></a><p></p>
<h3>Pregnancy Category D.</h3>
<p class="First">[See <a href="#i4i_section_id_c7d42fd1-36e1-4d63-9d9a-f5ee2d60bac2">Warnings and Precautions (5.8)</a>].</p>
<p>IFEX can cause fetal harm when administered to a pregnant woman. <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">Fetal growth retardation</span> and neonatal <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> have been reported following exposure to ifosfamide-containing chemotherapy regimens during pregnancy.</p>
<p>Animal studies indicate that ifosfamide is capable of causing gene mutations and chromosomal damage <span class="Italics">in vivo</span>. In pregnant mice, resorptions increased and anomalies were present at day 19 after a 30 mg/m<span class="Sup">2</span> dose of ifosfamide was administered on day 11 of gestation.  Embryo-lethal effects were observed in rats following the administration of 54 mg/m<span class="Sup">2</span> doses of ifosfamide from the 6th through the 15th day of gestation and embryotoxic effects were apparent after dams received 18 mg/m<span class="Sup">2</span> doses over the same dosing period.  Ifosfamide is embryotoxic to rabbits receiving 88 mg/m<span class="Sup">2</span>/day doses from the 6th through the 18th day after mating.  The number of anomalies was also significantly increased over the control group.</p>
<p>Women should not become pregnant and men should not father a child during therapy with ifosfamide.  Further, men should not father a child for up to 6 months after the end of therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug or after treatment, the patient should be apprised of the potential hazard to a fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_af22f49d-766a-423f-ae29-e202fa61c633"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Ifosfamide is excreted in breast milk.  Because of the potential for serious adverse events and the tumorigenicity shown for ifosfamide in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.  Women must not breastfeed during treatment with ifosfamide.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_c29a6250-8ffd-48a4-b0d0-e397470fe2e4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness have not been established in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_8310e877-4422-4d7a-a739-644ac1efd8ba"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>A study of patients 40 to 71 years of age indicated that elimination half-life appears to increase with advancing age [see <a href="#i4i_pharmacokinetics_id_2a61c5d3-ee44-488d-9b7c-a3293ffadf72">Pharmacokinetics (12.3)</a>].  This apparent increase in half-life appeared to be related to increases in volume of distribution of ifosfamide with age.  No significant changes in total plasma clearance or renal or non-renal clearance with age were reported.</p>
<p>Ifosfamide and its metabolites are known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa34a324-1d25-4cc2-96ee-b37d4b268b6a"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No formal studies were conducted in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Ifosfamide and its metabolites are known to be excreted by the kidneys and may accumulate in plasma with decreased renal function. Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be closely monitored for toxicity and dose reduction may be considered.  Ifosfamide and its metabolites are dialyzable<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7ff40b0-3e36-446a-82cb-08375353364e"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No formal studies were conducted in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Ifosfamide is extensively metabolized in the liver and forms both efficacious and toxic metabolites. IFEX should be given cautiously to patients with impaired hepatic function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_ea640c49-1d90-4925-80f0-ffa541df6b4f"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No specific antidote for IFEX is known.  </p>
<p>Patients who receive an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should be closely monitored for the development of toxicities.  Serious consequences of overdosage include manifestations of dose-dependent toxicities such as CNS toxicity, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> [see <a href="#i4i_warnings_precautions_id_2bf4b8fd-98db-4cd6-a836-bf59e7d8b5e9">Warnings and Precautions (5)</a>].</p>
<p>Management of overdosage would include general supportive measures to sustain the patient through any period of toxicity that might occur, including appropriate state-of-the-art treatment for any concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, or other toxicity.  Ifosfamide as well as ifosfamide metabolites are dialyzable.</p>
<p><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span> prophylaxis with mesna may be helpful in preventing or limiting urotoxic effects with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_c275556c-e066-4ed1-bc78-178eebeeada0"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">IFEX (ifosfamide for injection, USP) single-dose vials for constitution and administration by intravenous infusion each contain 1 gram or 3 grams of sterile ifosfamide.  Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide.  Ifosfamide is 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide.  The molecular formula is C<span class="Sub">7</span>H<span class="Sub">15</span>Cl<span class="Sub">2</span>N<span class="Sub">2</span>O<span class="Sub">2</span>P and its molecular weight is 261.1.  Ifosfamide is a white crystalline powder soluble in water.  There are no excipients in the formulation.  Each vial contains 1 gram or 3 grams of sterile ifosfamide alone.</p>
<p>Its structural formula is:</p>
<div class="Figure">
<a name="id927"></a><img alt="IFEX  Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b7241707-7538-4d1a-91e7-3a25a91e0b9a&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_5ab2dabe-7840-4679-b7e3-956b8a5fedeb"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_0f008e78-3ef3-4c7f-860f-34f2079959ba"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Ifosfamide is a prodrug that requires metabolic activation by hepatic cytochrome P450 isoenzymes to exert its cytotoxic activity.  Activation occurs by hydroxylation at the ring carbon atom forming the unstable intermediate 4-hydroxyifosfamide and its ring-opened aldo tautomer, which decomposes to yield the cytotoxic and urotoxic compound acrolein and an alkylating isophosphoramide mustard as well as multiple other nontoxic products.  The exact mechanism of action of ifosfamide has not been determined, but its cytotoxic action is primarily through DNA crosslinks caused by alkylation by the isophosphoramide mustard at guanine N-7 positions.  The formation of inter- and intra-strand cross-links in the DNA results in <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_2a61c5d3-ee44-488d-9b7c-a3293ffadf72"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Ifosfamide exhibits dose-dependent pharmacokinetics in humans.  At single doses of 3.8 to 5.0 g/m<span class="Sup">2</span>, the plasma concentrations decay biphasically and the mean terminal elimination half-life is about 15 hours.  At doses of 1.6 to 2.4 g/m<span class="Sup">2</span>/day, the plasma decay is monoexponential and the terminal elimination half-life is about 7 hours.</p>
<p>Ifosfamide exhibits time-dependent pharmacokinetics in humans. Following intravenous administration of 1.5 g/m<span class="Sup">2</span> over 0.5 hour once daily for 5 days to 15 patients with neoplastic disease, a decrease in the median elimination half-life from 7.2 hour on Day 1 to 4.6 hours on Day 5 occurred with a concomitant increase in the median clearance from 66 mL/min on Day 1 to 115 mL/min on Day 5. There was no significant change in the volume of distribution on Day 5 compared with Day 1. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6c85c0bf-7404-4f3b-8a37-d2e3699f9e00"></a><a name="section-11.2.1"></a><p></p>
<h3>Distribution</h3>
<p class="First">Ifosfamide volume of distribution (Vd) approximates the total body water volume, suggesting that distribution takes place with minimal tissue binding. Following intravenous administration of 1.5 g/m<span class="Sup">2</span> over 0.5 hour once daily for 5 days to 15 patients with neoplastic disease, the median Vd of ifosfamide was 0.64 L/kg on Day 1 and 0.72 L/kg on Day 5.  Ifosfamide shows little plasma protein binding. Ifosfamide and its active metabolites are extensively bound by red blood cells. Ifosfamide is not a substrate for P-glycoprotein.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_869c6762-6521-4a58-a0d4-d36605409fee"></a><a name="section-11.2.2"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Ifosfamide is extensively metabolized in humans through two metabolic pathways: ring oxidation ("activation") to form the active metabolite, 4-hydroxy-ifosfamide and side-chain oxidation to form the inactive metabolites, 3-dechloro-ethylifosfamide or 2-dechloroethylifosfamide with liberation of the toxic metabolite, chloroacetaldehyde. Small quantities (nmol/mL) of ifosfamide mustard and 4-hydroxyifosfamide are detectable in human plasma.  Metabolism of ifosfamide is required for the generation of the biologically active species and while metabolism is extensive, it is also quite variable among patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_11126748-c719-44ef-8158-cdb1492609f7"></a><a name="section-11.2.3"></a><p></p>
<h3>Excretion</h3>
<p class="First">After administration of doses of 5 g/m<span class="Sup">2</span> of <span class="Sup">14</span>C-labeled ifosfamide, from 70% to 86% of the dosed radioactivity was recovered in urine as metabolites, with about 61% of the dose excreted as parent compound.  At doses of 1.6 to 2.4 g/m<span class="Sup">2</span> only 12% to 18% of the dose was excreted in the urine as unchanged drug within 72 hours. Two different dechloroethylated derivatives of ifosfamide, 4-carboxyifosfamide, thiodiacetic acid and cysteine conjugates of chloroacetic acid have been identified as the major urinary metabolites of ifosfamide in humans and only small amounts of 4-hydroxyifosfamide and acrolein are present.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_710df451-f5d5-4a41-8b90-f9e9354d76a7"></a><a name="section-11.2.4"></a><p></p>
<h3>Pediatrics</h3>
<p class="First">Population PK analysis was performed on plasma data from 32 pediatric patients various malignant diseases aged between 1 and 18 years. Patients received a total of 45 courses of ifosfamide at doses of 1.2, 2.0 and 3.0 g/m<span class="Sup">2</span> given intravenously over 1 or 3 hours on 1, 2, or 3 days. The mean±standard error population estimates for the initial clearance and volume of distribution of ifosfamide were 2.4±0.33 L/h/m<span class="Sup">2</span> and 21±1.6 L/m<span class="Sup">2</span> with an interindividual variability of 43% and 32%, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_77bc5f72-709f-4b96-a5f1-abea70cf2263"></a><a name="section-11.2.5"></a><p></p>
<h3>Effect of Age</h3>
<p class="First">A study of 20 patients between 40 to 71 years of age receiving 1.5 g/m<span class="Sup">2</span> of ifosfamide daily for 3 or 5 days indicated that elimination half-life appears to increase with age.  The elimination half-life increase appeared to be related to the increase in ifosfamide volume of distribution with age.  No significant changes in total plasma clearance or renal clearance with age were reported.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_06282839-7a1a-4a93-8234-ac4a6b481266"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_62f5af42-0da2-42a4-b4ab-6f52139e8609"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Ifosfamide has been shown to be carcinogenic in rats when administered by intraperitoneal injection at 6 mg/kg (37 mg/m<span class="Sup">2</span>, or about 3% of the daily human dose on a mg/m<span class="Sup">2</span> basis) 3 times a week for 52 weeks.  Female rats had a significantly higher incidence of uterine leiomyosarcomas and mammary fibroadenomas than vehicle controls.  </p>
<p>The mutagenic potential of ifosfamide has been documented in bacterial systems <span class="Italics">in vitro</span> and mammalian cells <span class="Italics">in vivo</span>.  <span class="Italics">In vivo</span>, ifosfamide has induced mutagenic effects in mice and <span class="Italics">Drosophila melanogaster</span> germ cells, and has induced a significant increase in dominant lethal mutations in male mice as well as recessive sex-linked lethal mutations in Drosophila.</p>
<p>Ifosfamide was administered to male and female beagle dogs at doses of 1.00 or 4.64 mg/kg/day (20 or 93 mg/m<span class="Sup">2</span>) orally 6 days a week for 26 weeks.  Male dogs at 4.64 mg/kg (about 7.7% of the daily clinical dose on a mg/m<span class="Sup">2</span> basis) had <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> with degeneration of the seminiferous tubular epithelium.  In a second study, male and female rats were given 0, 25, 50, or 100 mg/kg (0, 150, 300, or 600 mg/m<span class="Sup">2</span>) ifosfamide intraperitoneally once every 3 weeks for 6 months.  Decreased spermatogenesis was observed in most male rats given 100 mg/kg (about half the daily clinical dose on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_f18efd5e-49b0-4d53-b133-b86d794ddb59"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Patients with refractory testicular cancer (n=59) received a combination of ifosfamide, cisplatin, and either etoposide (VePesid) or vinblastine (VIP) as third-line therapy or later. The selection of etoposide or vinblastine (“V? in the VIP regimen) was guided by the therapeutic effect achieved with prior regimens.  The contribution of ifosfamide to the VIP combination was determined in patients treated with cisplatin-etoposide prior to ifosfamide- cisplatin-etoposide or those who received cisplatin-vinblastine prior to ifosfamide-cisplatin-vinblastine.</p>
<p>A total of 59 patients received a third-line salvage regimen which consisted of ifosfamide 1.2 g/m<span class="Sup">2</span>/day intravenously on days 1 to 5, cisplatin 20 mg/m<span class="Sup">2</span>/day intravenously on days 1 to 5, and either etoposide 75 mg/m<span class="Sup">2</span>/day intravenously on days 1 to 5 or vinblastine 0.22 mg/kg intravenously on day 1.  Efficacy results with the VIP regimen were compared to data pooled from six single agent phase II trials conducted between August 1980 and October 1985 including a total of 90 patients of whom 65 were eligible as controls of this study.  Twenty-three patients in the VIP regimen became free of disease with VIP alone or VIP plus surgery, whereas a single patient in the historical control group achieved complete response.  The median survival time exceeded two years in the VIP group versus less than one year in the control group.  Performance status ≥ 80, embryonal carcinoma and minimal disease were favorable prognostic factors for survival.  In all prognostic categories, the difference between VIP and historical controls remained highly significant.</p>
<a name="_RefID2A3FA7F4CE0C4650AEB4CCF5F01F91AF"></a><table width="100%">
<caption><span>Table 1. Efficacy Results </span></caption>
<col width="33%">
<col width="23%">
<col width="23%">
<col width="21%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>Gehan-Breslow and Mantel-Cox tests</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Rrule Toprule" colspan="4"></td></tr>
<tr>
<td></td>
<td class="Botrule" align="center" colspan="2"><p class="First">Number. (%) of Patients</p></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule" align="center"><p class="First">VIP</p></td>
<td class="Botrule" align="center"><p class="First">Control</p></td>
<td class="Botrule Rrule" align="center"><p class="First">p-value</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Total Patients</p></td>
<td class="Botrule" align="center"><p class="First">59 (100)</p></td>
<td class="Botrule" align="center"><p class="First">65 (100)</p></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td><p class="First">Disease-free</p></td>
<td align="center"><p class="First">23 (39)</p></td>
<td align="center"><p class="First">1 (2)</p></td>
<td class="Rrule" align="center"><p class="First">&lt; 0.001</p></td>
</tr>
<tr>
<td><p class="First"> Chemotherapy alone</p></td>
<td align="center"><p class="First">15 (25)</p></td>
<td align="center"><p class="First">1 (2)</p></td>
<td class="Rrule" align="center"><p class="First">&lt; 0.001</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"> Chemotherapy plus surgery</p></td>
<td class="Botrule" align="center"><p class="First">8 (14)</p></td>
<td class="Botrule" align="center"><p class="First">0</p></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Overall Response</p></td>
<td class="Botrule" align="center"><p class="First">32 (54)</p></td>
<td class="Botrule" align="center"><p class="First">2 (3)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&lt; 0.001</p></td>
</tr>
<tr>
<td><p class="First">Time to progression (weeks)</p></td>
<td></td>
<td></td>
<td class="Rrule"></td>
</tr>
<tr>
<td><p class="First"> Median</p></td>
<td align="center"><p class="First">19</p></td>
<td align="center"><p class="First">4</p></td>
<td class="Rrule" align="center"><p class="First">&lt; 0.001<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"> Range</p></td>
<td class="Botrule" align="center"><p class="First">1 – 205+</p></td>
<td class="Botrule" align="center"><p class="First">1 – 29</p></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td><p class="First">Disease-free interval (weeks)</p></td>
<td></td>
<td></td>
<td class="Rrule"></td>
</tr>
<tr>
<td><p class="First"> Median</p></td>
<td align="center"><p class="First">114</p></td>
<td align="center"><p class="First">29</p></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Botrule"><p class="First"> Range</p></td>
<td class="Botrule" align="center"><p class="First">13 – 205+</p></td>
<td class="Botrule" align="center"><p class="First">--</p></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td><p class="First">Survival (weeks)</p></td>
<td></td>
<td></td>
<td class="Rrule"></td>
</tr>
<tr>
<td><p class="First"> Median</p></td>
<td align="center"><p class="First">53</p></td>
<td align="center"><p class="First">10</p></td>
<td class="Rrule" align="center"><p class="First">&lt; 0.001<a href="#footnote-15" class="Sup">*</a></p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"> Range</p></td>
<td class="Botrule" align="center"><p class="First">1 – 205+</p></td>
<td class="Botrule" align="center"><p class="First">1 – 123+</p></td>
<td class="Botrule Rrule"></td>
</tr>
</tbody>
</table>
<p>In a study, 50 fully evaluable patients with germ cell testicular cancer were treated with IFEX in combination with cisplatin and either vinblastine or etoposide after failing (47 of 50 patients) at least two prior chemotherapy regimens consisting of cisplatin/vinblastine/bleomycin, (PVB), cisplatin/vinblastine/actinomycin D/bleomycin/cyclophosphamide, (VAB6), or the combination of cisplatin and etoposide.  Patients were selected for remaining cisplatin sensitivity because they had previously responded to a cisplatin containing regimen and had not progressed while on the cisplatin containing regimen or within 3 weeks of stopping it.  Patients served as their own control based on the premise that long term complete responses could not be achieved by retreatment with a regimen to which they had previously responded and subsequently relapsed.</p>
<p>Ten of 50 fully evaluable patients were still alive 2 to 5 years after treatment.  Four of the 10 long term survivors were rendered free of cancer by surgical resection after treatment with the ifosfamide regimen; median survival for the entire group of 50 fully evaluable patients was 53 weeks.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_cdec1d69-31eb-4d3e-aa54-36637a5422a9"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.</dd>
<dt>2.</dt>
<dd>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling occupational exposure to hazardous drugs. OSHA, 1999. <a href="http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html">http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</a>. </dd>
<dt>3.</dt>
<dd>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. <span class="Italics">Am J Health-Syst Pharm</span>. 2006; 63:1172-1193.</dd>
<dt>4.</dt>
<dd>Polovich M, White JM, Kelleher LO, (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice. (2<span class="Sup">nd</span> ed.) Pittsburgh, PA: Oncology Nursing Society.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_f7baa128-d182-4f04-8668-0d8a7ca5f2b4"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">IFEX (ifosfamide for injection, USP) is available in single-dose vials as follows:</p>
<dl>
<dt> </dt>
<dd>IFEX (ifosfamide for injection)</dd>
<dt> </dt>
<dd>NDC 0338-3991-01 1-gram Single-Dose Vial</dd>
<dt> </dt>
<dd>NDC 0338-3993-01 3-gram Single-Dose Vial</dd>
</dl>
<p>Store at controlled room temperature 20°C to 25°C (68°F to 77°F).</p>
<p>Protect from temperatures above 30°C (86°F).</p>
<p>Exercise caution when handling IFEX.  The handling and preparation of ifosfamide should always be in accordance with current guidelines on safe handling of cytotoxic agents.  Several guidelines on this subject have been published.<span class="Sup">1-4</span> <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span> associated with accidental exposure to IFEX may occur.  To minimize the risk of dermal exposure, always wear impervious gloves when handling vials and solutions containing IFEX.  If IFEX solution contacts the skin or mucosa, immediately wash the skin thoroughly with soap and water or rinse the mucosa with copious amounts of water.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_8cfac4e8-1e3e-426c-b3b3-d8e5029a2fe7"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Inform patients of the risks associated with the use of IFEX as well as the plan for regular blood monitoring during therapy.</p>
<p>Specifically inform patients of the following:</p>
<dl>
<dt>•</dt>
<dd>Treatment with ifosfamide may cause <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> which can be severe and lead to fatal outcome.  Significant suppression of immune responses can also occur which can lead to severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  Latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be reactivated.  Patients should report <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</dd>
<dt>•</dt>
<dd>The risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</dd>
<dt>•</dt>
<dd>The risk of CNS toxicity and other neurotoxic effects with fatal outcome.</dd>
<dt>•</dt>
<dd>The risk of bladder and kidney toxicity.  Patients should be aware of the need to increase fluid intake and frequent voiding to prevent accumulation in the bladder.</dd>
<dt>•</dt>
<dd>The risk of cardiotoxicity and fatal outcome.  Patients should report preexisting cardiac disease.</dd>
<dt>•</dt>
<dd>The risk of pulmonary toxicity leading to <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> with fatal outcome.</dd>
<dt>•</dt>
<dd>The risk of secondary malignancies due to therapy.</dd>
<dt>•</dt>
<dd>The risk of veno-occlusive liver disease.</dd>
<dt>•</dt>
<dd>The potential hazard to a fetus if a patient becomes pregnant or fathers a child during therapy and for up to 6 months after therapy.  Effective methods of contraception should be used during therapy and for up to 6 months after therapy.</dd>
<dt>•</dt>
<dd>The potential for serious adverse reactions and tumorigenicity when children are breastfed during therapy.</dd>
<dt>•</dt>
<dd>The risk of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="198715" conceptname="Premature menopause">premature menopause</span>, and <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span>.</dd>
<dt>•</dt>
<dd>The risk of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, and other serious skin and subcutaneous tissue disorders.</dd>
<dt>•</dt>
<dd>Therapy may cause <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> and alcohol may increase <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</dd>
<dt>•</dt>
<dd>The risk of <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> and the importance of proper oral hygiene.</dd>
<dt>•</dt>
<dd>The risk of <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">eye disorders</span> such as <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, and <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>.</dd>
<dt>•</dt>
<dd>The risk of ear and labyrinth disorders such as <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_642a7dcd-fb07-4990-81de-246079aaf2d7"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Baxter Logo</span></span><br>Manufactured by:<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>For Product Inquiry 1800 ANA DRUG (1-800-262-3784)</p>
<p>Made in Germany</p>
<p>Baxter, Ifex and Viaflex are trademarks of Baxter International Inc.</p>
<p>PAB is trademark of B Braun</p>
<p>HA-30-01-425</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b3f8f27f-0627-4a21-9c29-9f06d9f489e6"></a><a name="section-18"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPLE DISPLAY PANEL</h1>
<div class="Figure">
<a name="id1147"></a><img alt="IFEX Container Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b7241707-7538-4d1a-91e7-3a25a91e0b9a&amp;name=image-02.jpg"><p class="MultiMediaCaption">IFEX Container Label </p>
</div>
<p class="First">IFEX Container Label </p>
<p><span class="Bold">NDC 0338-3991-01</span></p>
<p><span class="Bold">IFEX </span><br><span class="Bold">IFOSFAMIDE FOR INJECTION, USP</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">1 g</span></p>
<p>SINGLE-DOSE VIAL</p>
<p>This vial contains 1g ifosfamide.<br>Add 20 mL Sterile Water for <br>Injection, USP, or Sterile <br>Bacteriostatic Water for Injection, <br>USP, (benzyl alcohol or parabens <br>preserved), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> to dissolve, <br>for a reconstituted concentration <br>of 50 mg per mL.</p>
<p><span class="Bold">Store at controlled room </span><br><span class="Bold">temperature 20° C to 25° C </span><br><span class="Bold">(68° F to 77° F)</span></p>
<p><span class="Bold">Protect from temperatures </span><br><span class="Bold">above 30° C (86° F).</span></p>
<p><span class="Bold">FOR IV USE</span></p>
<p><span class="Bold">READ ACCOMPANYING </span><br><span class="Bold">PACKAGE INSERT for detailed </span><br><span class="Bold">indications, dosage, and </span><br><span class="Bold">precautions. </span></p>
<p>Manufactured by: <br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>USA 5561 0780 C 85</p>
<p>Bar Code<br>N(01)1 03 0338 3991 01 7</p>
<p>Lot:/Exp.:</p>
<div class="Figure">
<a name="id1190"></a><img alt="IFEX Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b7241707-7538-4d1a-91e7-3a25a91e0b9a&amp;name=image-03.jpg"><p class="MultiMediaCaption">IFEX Carton Label </p>
</div>
<p>IFEX Carton Label </p>
<p><span class="Bold">1 vial</span></p>
<p><span class="Bold">NDC 0338-3991-01</span></p>
<p><span class="Bold">IFEX</span><br><span class="Bold">(ifosfamide for injection, USP)</span></p>
<p><span class="Bold">Single-Dose Vial</span><br><span class="Bold">FOR IV USE</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">1 g</span></p>
<p><span class="Bold"><span class="Italics">Baxter Logo</span></span><br>Manufactured by<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>See bottom panel for lot<br>number and expiration date.</p>
<p>Bar Code<br>N3 0338399101 0</p>
<p>This vial contains 1 g ifosfamide. Add<br>20 mL Sterile Water for Injection, USP, <br>or Sterile Bacteriostatic Water for <br>Injection, USP, (benzyl alcohol or <br>parabens preserved), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> to <br>dissolve, for a reconstituted <br>concentration of 50 mg per mL.</p>
<p><span class="Bold">READ ACCOMPANYING PACKAGE </span><br><span class="Bold">INSERT for detailed indications, </span><br><span class="Bold">dosage, and precautions.</span></p>
<p><span class="Bold">Store at controlled room </span><br><span class="Bold">temperature 20° C to 25° C </span><br><span class="Bold">(68° F to 77° F). Protect from </span><br><span class="Bold">temperatures above 30° C (86° F).</span></p>
<p>Constituted solutions should be <br> refrigerated and used within 24 hours.</p>
<p>Manufactured by:<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA<br>Made in Germany</p>
<div class="Figure">
<a name="id1242"></a><img alt="Representative Ifex Container Label 0338-3993-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b7241707-7538-4d1a-91e7-3a25a91e0b9a&amp;name=image-04.jpg">
</div>
<p><span class="Bold">NDC 0338-3993-01</span></p>
<p><span class="Bold">IFEX </span><br><span class="Bold">IFOSFAMIDE FOR INJECTION, USP </span></p>
<p><span class="Bold">Rx only </span></p>
<p><span class="Bold">3 g </span></p>
<p>SINGLE-DOSE VIAL</p>
<p>This vial contains 3g ifosfamide.<br>Add 60 mL Sterile Water for <br>Injection, USP, or Sterile <br>Bacteriostatic Water for Injection, <br>USP, (benzyl alcohol or parabens <br>preserved), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> to dissolve, <br>for a reconstituted concentration <br>of 50 mg per mL.</p>
<p><span class="Bold">Store at controlled room </span><br><span class="Bold">temperature 20° C to 25° C </span><br><span class="Bold">(68° F to 77° F) </span></p>
<p><span class="Bold">Protect from temperatures </span><br><span class="Bold">above 30° C (86° F). </span></p>
<p><span class="Bold">FOR IV USE </span><br><span class="Bold">READ ACCOMPANYING </span><br><span class="Bold">PACKAGE INSERT for detailed </span><br><span class="Bold">indications, dosage, and </span><br><span class="Bold">precautions.  </span></p>
<p>Manufactured by: <br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p><span class="Bold">USA</span> 5561 0790 C 86</p>
<p>Bar Code<br>N(01)1 03 0338 3993 01 1</p>
<p>Lot:/Exp.:</p>
<p><span class="Bold">JMXXX</span></p>
<p><span class="Bold">MM.JJJJ</span></p>
<div class="Figure">
<a name="id1292"></a><img alt="Ifex Representative Carton Label 0338-3993-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b7241707-7538-4d1a-91e7-3a25a91e0b9a&amp;name=image-05.jpg">
</div>
<p><span class="Bold">1 vial </span></p>
<p><span class="Bold">NDC 0338-3993-01 </span></p>
<p><span class="Bold">IFEX</span><br><span class="Bold">(ifosfamide for injection, USP) </span></p>
<p><span class="Bold">Single-Dose Vial</span><br><span class="Bold">FOR IV USE </span></p>
<p><span class="Bold">Rx only </span></p>
<p><span class="Bold">3 g </span></p>
<p><span class="Bold"><span class="Italics">Baxter Logo</span></span><br>Manufactured by<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA</p>
<p>See bottom panel for lot<br>number and expiration date.</p>
<p>Bar Code<br>N3 0338399301 4</p>
<p>This vial contains 3 g ifosfamide. <br>Add 60 mL Sterile Water for Injection, USP, <br>or Sterile Bacteriostatic Water for <br>Injection, USP, (benzyl alcohol or <br>parabens preserved), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> to <br>dissolve, for a reconstituted <br>concentration of 50 mg per mL.</p>
<p><span class="Bold">READ ACCOMPANYING PACKAGE </span><br><span class="Bold">INSERT for detailed indications, </span><br><span class="Bold">dosage, and precautions.</span></p>
<p><span class="Bold">Store at controlled room </span><br><span class="Bold">temperature 20° C to 25° C </span><br><span class="Bold">(68° F to 77° F). Protect from </span><br><span class="Bold">temperatures above 30° C (86° F).</span></p>
<p>Constituted solutions should be <br> refrigerated and used within 24 hours.</p>
<p>Manufactured by:<br><span class="Bold">Baxter Healthcare Corporation</span><br>Deerfield, IL 60015 USA<br>Made in Germany</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IFEX 		
					</strong><br><span class="contentTableReg">ifosfamide injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-3991</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IFOSFAMIDE</strong> (IFOSFAMIDE) </td>
<td class="formItem">IFOSFAMIDE</td>
<td class="formItem">1 g  in 20 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-3991-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019763</td>
<td class="formItem">12/30/1988</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IFEX 		
					</strong><br><span class="contentTableReg">ifosfamide injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-3993</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IFOSFAMIDE</strong> (IFOSFAMIDE) </td>
<td class="formItem">IFOSFAMIDE</td>
<td class="formItem">3 g  in 60 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-3993-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019763</td>
<td class="formItem">12/30/1988</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(005083209)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Oncology GmbH</td>
<td class="formItem"></td>
<td class="formItem">344276063</td>
<td class="formItem">ANALYSIS(0338-3991, 0338-3993), MANUFACTURE(0338-3991, 0338-3993), LABEL(0338-3991, 0338-3993), PACK(0338-3991, 0338-3993), STERILIZE(0338-3991, 0338-3993)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5ec97e1e-34bb-428b-b837-72dece080855</div>
<div>Set id: b7241707-7538-4d1a-91e7-3a25a91e0b9a</div>
<div>Version: 7</div>
<div>Effective Time: 20140828</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
